PMC

A. stratified for patients treated for localized (solid line) versus metastatic disease (dotted line); B. stratified for R0 (solid line) versus R1 (dotted line) resection; C. stratified for tumors <5cm (solid line) versus ≥5cm; and, D. stratified for primary (solid line) versus recurrent (dotted line) disease at presentation.

Representative sequence chromatograms of the three most commonly occurring p53 mutations in PLS samples and tabulation of p53 mutational status and protein expression levels in individual PLS samples.

A. “Heatmap” summarizing expression levels of each of the proteins evaluated in all individual scorable samples (* VEGF was only scored as positive or negative); B. Immunohistochemical images demonstrating representative levels of evaluated markers in human PLS specimens (controls included as insets: PPARγ = low expressing PLS, adipophilin = DDLPS, BCL2 = low expressing PLS, survivin = low expressing UPS/MFH, p16 = low expressing PLS, Rb = high expressing PLS, CDK4 = DDLPS, VEGF = negative expression PLS, MMP2&9 = negative expressing PLSs, EGFR = low expressing PLS, MDM2 = DDLPS, p53 = low expressing PLS). All original images were captured at ×200 magnification.